Alzheimer's and Parkinson's: The Highest Level of Evidence in Agarwood Research, and Why We Still Can't Say 'Cure'

The Agarwood and Neurodegenerative Disease Research Literature Collection contains 49 entries and represents the highest level of evidence among the five collections: the only agarwood research direction with a randomized controlled clinical trial. But "highest level of evidence" and "can treat Alzheimer's disease" are two different statements, and this article clarifies both sides.

1. Tradition and Modern Science Close the Loop Here

Agarwood is a traditional "aromatic orifice-opening medicine"; the Compendium of Materia Medica's use to "clear the spirit" and Tibetan medicine's use to "manage emotions" have been passed down for millennia. The rationale of Wang Yuehu's team at the Kunming Institute of Botany is precisely the hypothesis that "aromatic compounds readily cross the blood-brain barrier"—incense inhalation is the most classic use of agarwood and happens to be the most favorable route of administration for the neurological direction. Traditional efficacy, modern mechanisms, and clinical evidence form a closed loop; this direction is the most complete.

2. The Most Significant Findings

① Memory impairment animal study (Frontiers in Pharmacology 2021). In scopolamine-induced memory impairment in C57BL/6 mice, inhaled agarwood improved learning and memory as cross-validated by three behavioral paradigms (water maze / novel object recognition / social discrimination), with overall efficacy superior to the positive control drug donepezil—this is the ceiling of animal evidence in the neurological direction.

② Antidepressant mechanism (Pharmaceuticals 2025). In the LPS depression model, dual-route validation by inhalation and injection, with behavioral plus molecular evidence at two levels: inhibition of the NF-κB/IκB-α inflammatory pathway and activation of the BDNF/TrkB/CREB trophic pathway. An interesting detail: steam-distilled agarwood oil outperformed supercritical extraction—suggesting the activity comes mainly from sesquiterpenes.

③ New pathological target (Biomedicines 2025). For the first time, anti-tau aggregation components were sought from agarwood (one of the core pathologies of Alzheimer's disease); octahydrocurcumin was included, and "secondary metabolites" were rediscovered.

3. Three Buckets of Cold Water

First, the only RCT targets insomnia, not dementia or Parkinson's—there is no bridge whatsoever between "human evidence for improving sleep" and "treating neurodegenerative disease." Second, acetylcholinesterase inhibitory activity (15.8%–49.9%) is far inferior to donepezil and huperzine A; the realistic positioning is as a source of lead compounds, not as a drug. Third, no study has demonstrated that agarwood can alter disease course; all data are short-term neuroprotective indicators. Incidentally, let's correct a hard error circulating online: the claim that "agarwood promotes serotonin reuptake" has the mechanism completely backwards—antidepressants actually inhibit reuptake. There is also an industry easter egg: the sum of relative chromone content differs by 66%–85% between qinan and ordinary agarwood, and this gap itself can serve as a chemical indicator for authenticity identification.

This article is a review of research literature, for academic reference only, and does not constitute medical advice, let alone any disease treatment plan. Please follow medical advice for related health issues. The bibliographic information in this article was compiled by the Wubaiyi Agarwood Research Center and the Zhongke Agarwood Standard Technology Research Institute's Agarwood Research Literature Collection series (October 2026); please verify the original literature before citing specific data.